glp 1 agonist comparison of short-acting versus long-acting GLP-1 receptor agonists π΄Comparison of GLP-1R Mono-Agonist vs.
Description
Conflict of Interest Statement S.L.B
(20) Baseline measurements of total, pelvic, and arm-leg BMC, CTX-1 and Procollagen Type I N-terminal propeptide (P1NP) were obtained before participants were assigned to the study or control group

This seems to lower blood sugar and improve insulin response in people with diabetes

DPP-4 inhibitors (DPP-4i) block degradation of GLP-1 and GIP, extend their insulinotropic effect, and improve glycemia [26]

Its working more so on the brain and having that signaling then be able to impact that peripheral system

Risks include gastrointestinal side effects, pancreatitis, gallbladder disease, and a boxed warning for thyroid C-cell tumors
